Company profile for Alnylam Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam marked by it...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
300 Third Street 3rd Floor Cambridge, MA 02142
Telephone
Telephone
617.551.8200
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-12-03/alnylam-pharmaceuticals-announces-changes-to-board-of-directors

PHARMIWEB
03 Dec 2025

https://www.fiercebiotech.com/biotech/letter-makary-biotech-ceos-push-fda-stability-and-say-volatility-threatens-us-innovation

FIERCE BIOTECH
21 Nov 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/uks-drug-cost-watchdog-recommends-alnylams-heart-disease-drug-2025-11-21/

REUTERS
21 Nov 2025

https://www.businesswire.com/news/home/20251108898772/en/New-Post-Hoc-Analysis-from-the-HELIOS-B-Phase-3-Study-Shows-Vutrisiran-Improved-Measures-of-Heart-Structure-and-Function-in-Patients-with-ATTR-CM

BUSINESSWIRE
08 Nov 2025

https://www.businesswire.com/news/home/20251104566593/en/Alnylam-to-Webcast-Presentations-at-Upcoming-November-Investor-Conferences

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251030005751/en/Alnylam-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Period-Progress

BUSINESSWIRE
30 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty